1 BTC
=
- USD
Lyell Immunopharma, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Lyell Immunopharma, Inc. Common Stock
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Market Statistics
Trading Metrics
How to Buy LYEL
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy LYEL
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesLyell Immunopharma closed an additional $50 million tranche from its $100 million equity private placement following achievement of a clinical milestone for rondecabtagene autoleucel (ronde-cel) in its PiNACLE pivotal trial for relapsed/refractory large B-cell lymphoma. The company also appointed Smital Shah as Chief Financial and Business Officer. With this funding, Lyell expects sufficient cash runway into Q2 2027.
Lyell Immunopharma reported promising clinical trial results for ronde-cel, a CAR T-cell therapy targeting large B-cell lymphoma, showing high response rates and a manageable safety profile across multiple treatment lines.
Lyell Immunopharma presented clinical trial data for ronde-cel, a dual-targeting CD19/CD20 CAR T-cell therapy for aggressive large B-cell lymphoma, highlighting promising response rates and safety profile at the 67th ASH Annual Meeting.
